Bill
Bill > H4865
MA H4865
Relative to certain genetically targeted drug coverage for Duchenne Muscular Dystrophy
summary
Introduced
07/31/2018
07/31/2018
In Committee
08/06/2018
08/06/2018
Crossed Over
07/31/2018
07/31/2018
Passed
Dead
12/31/2018
12/31/2018
Introduced Session
190th General Court
Bill Summary
Substituted by the House, on motion of Mr. Speliotis of Danvers, for a bill with the same title (House, No. 3644). July 31, 2018.
AI Summary
This bill requires certain health insurance plans in Massachusetts, including the Group Insurance Commission, MassHealth, and private insurers, to provide coverage for genetically targeted drugs for Duchenne muscular dystrophy. The drugs must be approved by the FDA, including through the accelerated approval process, and determined to be medically necessary by a physician with expertise in Duchenne muscular dystrophy. The bill also limits the out-of-pocket costs for these drugs and includes an exception if the drug price increases significantly more than the Consumer Price Index or if the manufacturer does not comply with state transparency requirements.
Committee Categories
Budget and Finance
Sponsors (1)
Last Action
Read; and referred to the committee on Senate Ways and Means (on 08/06/2018)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://malegislature.gov/Bills/190/H4865 |
| Bill | https://malegislature.gov/Bills/190/H4865.pdf |
Loading...